Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E known ✓ | A5X5Y0 | 1/20 | 0.55 |
| ▸ | HTR3B known ✓ | O95264 | 1/20 | 0.55 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.55 |
| ▸ | HTR3D known ✓ | Q70Z44 | 1/20 | 0.55 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 1/20 | 0.55 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.47 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.47 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.47 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.47 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.47 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.47 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 3/20 | 0.56 |
| ▸ | NOS1 | P29475 | 3/20 | 0.52 |
| ▸ | NOS3 | P29474 | 1/20 | 0.52 |
| ▸ | NOS2 | P35228 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1238345 | 0.97 | HTR3E (0.57) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| Bicarbonate SCHEMBL6989215 | 0.91 | CES1 (0.56) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL13673467 | 0.89 | PLA2G10 (0.53) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| Acetic Acid SCHEMBL3665413 | 0.87 | CES1 (0.52) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL27868161 | 0.85 | HTR3E (0.47) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5756341 | 0.84 | LMNA (0.57) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL26633566 | 0.82 | MAOB (0.62) | PRSS1PRSS2PRSS3F2F10 | |
| SCHEMBL11344724 | 0.80 | TSHR (0.57) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2810781 | 0.80 | HTR3E (0.73) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Phenylacetic Acid SCHEMBL28326941 | 0.79 | AKR1B1 (0.74) | IDO1NOS1NOS3NOS2CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120166906-A | Two-dimensional/three-dimensional perovskite heterojunction based on amidino cation and application of perovskite heterojunction in solar cell | 西安交通大学 | 2025-06-17 | — | — | CN | claimed |
| CN-112159411-A | Trifluoromethyl substituted pyrimido [1,3] diaza compound and preparation method thereof | 南京工业大学 | 2021-01-01 | — | — | CN | claimed |
| CN-106083859-B | Preparation method of imipenem monohydrate crystal | 山东新时代药业有限公司 | 2021-01-01 | — | — | CN | claimed |
| CN-120166906-A | Two-dimensional/three-dimensional perovskite heterojunction based on amidino cation and application of perovskite heterojunction in solar cell | 西安交通大学 | 2025-06-17 | — | — | CN | disclosed |
| CN-119390654-A | Preparation method of polysubstituted imidazole derivative | 广东省科学院化工研究所 | 2025-02-07 | — | — | CN | disclosed |
| CN-113644206-A | Micron-sized perovskite thick film and preparation method and application thereof | 西湖大学 | 2021-11-12 | — | — | CN | disclosed |
| CN-112159411-A | Trifluoromethyl substituted pyrimido [1,3] diaza compound and preparation method thereof | 南京工业大学 | 2021-01-01 | — | — | CN | disclosed |
| CN-106083859-B | Preparation method of imipenem monohydrate crystal | 山东新时代药业有限公司 | 2021-01-01 | — | — | CN | disclosed |
| CN-106083859-B | Preparation method of imipenem monohydrate crystal | 山东新时代药业有限公司 | 2021-01-01 | — | — | CN | disclosed |
| US-20190201404-A1 | THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2019-07-04 | — | — | US | disclosed |
| US-10278972-B2 | Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2019-05-07 | — | — | US | disclosed |
| EP-0469685-A1 | Tetrahydropyrimidine derivatives | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1992-02-05 | — | — | EP | disclosed |
| US-4871739-A | Substituted 6H-7,8-dihydrothiapyrano(3,2-D)-pyrimidines as hyopglycemic agents | MERCK & CO., INC. (US) | 1989-10-03 | — | — | US | disclosed |
| US-4522763-A | STARTING MATERIALS FOR CROP PROTECTION AGENTS AND SELECTIVE HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1985-06-11 | — | — | US | disclosed |
| US-4505910-A | Amino-pyrimidine derivatives, compositions and use | AMERICAN HOME PRODUCTS CORPORATION (US) | 1985-03-19 | — | — | US | disclosed |
| EP-0130735-A1 | Amino-pyrimidine derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1985-01-09 | — | — | EP | disclosed |
| US-4278673-A | Pharmacologically active compounds | ALLEN & HANBURYS LIMITED (GB) | 1981-07-14 | — | — | US | disclosed |
| US-RE30511-E | ENZYME INHIBITOR, HERBICIDE, CYCLIZATION | AMERICAN CYANAMID COMPANY (US) | 1981-02-10 | — | — | US | disclosed |
| US-4168964-A | HERBICIDES | AMERICAN CYANAMID COMPANY (US) | 1979-09-25 | — | — | US | disclosed |
| US-4107307-A | ENZYME INHIBITORS, HERBICIDES, RING CLOSURE | AMERICAN CYANAMID COMPANY (US) | 1978-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10278972-B2 | Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them | TYMS, TYMP, TPX2 | HTR3E 2843/4885HTR3B 2046/4885HTR3A 3713/4885 |
| US-20190201404-A1 | THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TYMS, TYMP, TPX2 | HTR3E 2843/4885HTR3B 2046/4885HTR3A 3713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.